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Abstract
Background: Classic Kaposi’s sarcoma is a lymphatic endothelial cell neoplasm usually present on the skin of
the upper and lower extremities. Although it commonly affects human immunodeficiency virus positive
patients, there have been some human immunodeficiency virus negative cases reported. We report an
uncommon presentation of stage IV classic Kaposi’s sarcoma in an human immunodeficiency virus negative
patient in Latin America with complete clinical response using only radiation therapy treatment.
Case presentation: A 78-year-old Mexican man with no evidence of human immunodeficiency virus
infection presented with a painful widespread dermatosis with maculopapular, nodular, violaceous lesions on
his legs and ulcerated lesions on his feet. A biopsy confirmed the lesions as classic Kaposi’s sarcoma.
Radiotherapy treatment was delivered, prescribing a total dose of 30 Gy in 15 fractions with a complete
clinical response within 15 months of follow-up.
Conclusions: This is an unusual case since it is uncommon to use radiation therapy as the single treatment
in stage IV classic Kaposi’s sarcoma; the efficacy of the treatment is shown in the impact in our patient’s
recurrence-free survival, local control, and palliation of our patient’s symptoms.
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Background
Kaposi’s sarcoma (KS) is a malignant neoplasm of
lymphatic endothelial cells defined for the first time in
1872 [1]. A Hungarian dermatologist, Moritz Kaposi,
named it as “idiopathic multiple pigmented sarcoma”,
also known as “Kaposi’s angiosarcoma” or “idiopathic
multiple hemorrhagic sarcoma”. KS is a systemic angio-
matosis with malignant evolution, which is initially
manifested as multiple vascular nodules in the skin and
other organs [2, 3]. Classic Kaposi’s sarcoma (CKS)
mostly affects people of Mediterranean background and
Jewish origin, Italy and Turkey being the countries with
the highest frequency of the disease. CKS appears
between the fifth and seventh decade of life and is more
common in males than females with a ratio of 15 to 1.
The most frequent location is the lower extremities
with cutaneous affectation and centripetal extension.
Tumors and nodules can either be covered by normal
skin, atrophic skin or ulcerated; some others may have a
wart-like or fungal surface. The lesions can be painful,
edematous and hemorrhagic, limiting patient ambula-
tion. The damage may appear on internal organs or be
only visceral without any cutaneous lesions. Despite the
fact that any internal organ can be affected, it can also
appear without cutaneous lesions and exclusive visceral
affection. The affection of the lungs or lymph nodes it is
not frequent. Death can be a consequence of generalized
disease with cachexia, hemorrhage, or impairment of
vital organs function by tumor growth [4, 5].
The following table shows a classification of the most
common forms found in the current literature, which
divides CKS into four stages [6] (Table 1).
Case presentation
A 78-year-old Mexican man with no evidence of human
immunodeficiency virus (HIV) infection presented with a
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history of two cardiac catheterizations, longstanding
hypertension, high-risk prostate cancer treated with total
androgenic blockage and radiation therapy (RT). Our pa-
tient also presented a painful widespread dermatosis
with maculopapular, nodular, violaceous lesions on
his legs and ulcerated lesions on his feet, limiting
our patient’s ambulation for a year (Fig. 1). In order
to confirm the diagnosis of CKS, an incisional biopsy
was performed on our patient; the result was non-
HIV-associated CKS without immunosuppression
(Fig. 2). The final diagnosis was: dispersed and ag-
gressive stage IV CKS. Our patient was not a candi-
date for systemic therapy due to the comorbidities
and the high toxicity risk. Radiotherapy was decided
as the single treatment with the Clinac iX energy
6MV equipment (Varian Medical Systems, Inc., Palo
Alto, CA, USA), using two fields of treatment and
100 % of the prescription dose, giving a total dose of
3000 cGy in 15 fractions, 200 cGy per fraction, and
a bolus of 0.5 cm doses to the surface. An increase
in electrons for his heels with a 0.5 cm depth from
the skin was considered (Fig. 3).
Discussion
Treatment for classic Kaposi’s sarcoma is mainly palliative.
Multidisciplinary treatment methods with different re-
sponses are applied to CKS therapy such as intralesional
interferon alpha, cryotherapy, hormone therapy, laser re-
moval, systemic chemotherapy, infrared coagulation and
radiotherapy depending on the clinical form [7]. Radiother-
apy is a useful method to improve the quality of life in pa-
tients with CKS and the response to treatment usually
carries minimal toxicity [8]. CKS is generally considered
sensitive to radiation therapy with good palliative and es-
thetic results, demonstrated with doses greater than 20 Gy
[9]. In this sense in the literature, a standard dose of treat-
ment is not mentioned; however, radiotherapy hypofractio-
nation has demonstrated to have an impact in terms of
recurrence-free survival, toxicity, and local control [10]. For
those patients with a limited life expectancy one fraction
with 800 cGy has shown to provide successful outcomes
[11]. In this case, the dose of 30 Gy in sessions of 2 Gy per
fraction in combination with electron therapy in the same
dosage in the lesions had a complete response on his feet,
along with the relief of symptoms and improvement in life
quality of our patient.
Table 1 Staging of classic Kaposi’s sarcoma
Lesions Location Behavior Evolution Complications
I Nodules/macules Legs Nonaggressive A - slow B - fast Lymphedema lymphorrhea
II Plaques Legs Locally aggressive A - slow B - fast Hemorrhage
III Angiomatous plaques and nodules Limbs Locally aggressive A - slow B - fast Functional damage
IV Angiomatous plaques and nodules Limbs, trunk, head Disseminated B - fast Ulceration
Stages I and II are subdivide into:
Group A: slow progression
Group B: rapid progression with an increased number of plates/nodules or the extension that the nodules occupy in 3 months since the last scan
Stages III and IV present more gastrointestinal and visceral affectation
Fig. 1 Cutaneous lesions affected the lower extremities in a
symmetrical fashion, mainly heels and toes. Lesions reduced in
size after treatment with radiation therapy. After 15 months of
radiotherapy, a complete response was observed in his feet with
improved mobility, complete disappearance of pain, and without
significant toxicity
Ramírez et al. Journal of Medical Case Reports  (2016) 10:322 Page 2 of 4
Conclusions
It is uncommon to use radiation therapy as the single
treatment in stage IV classic Kaposi’s sarcoma, the
efficacy of the treatment is shown in the impact in our
patient’s recurrence-free survival, local control, and
palliation of patient symptoms.
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Fig. 2 Kaposi’s sarcoma at low magnification. Kaposi’s sarcoma is mainly composed of spindle cells separated by vascular channels
Fig. 3 Field of treatment with Clinac iX equipment, two field photon mode
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